Raykov Rosty’s SEC Form 4 filings over the past year paint a one-sided picture: a steady stream of open-market sales in a single company, Fennec Pharmaceuticals (FENC), with no corresponding purchases. Across 36 total transactions, Rosty has sold roughly $1.09 million worth of stock while acquiring nothing on the open market. The recent activity is entirely sell-side, with nine open-market sales (coded “S”) in the last several months, punctuated by option exercises (coded “M”) and equity awards (coded “A”) that carry no cash value and are compensation, not conviction buys.
The pattern is mechanical and recurring. From November 2025 through July 2026, Rosty executed a sale on the first trading day of nearly every month, with values ranging from roughly $69,000 to $99,900. For example, a July 1, 2026 sale brought in $99,925.59, following a June 1 sale of $93,766.14 and a May 1 sale of $69,753.07. Each sale is paired with an option exercise of approximately $38,200, suggesting the shares sold are sourced from exercised options rather than accumulated open-market positions. The monthly rhythm—sell, exercise, receive a zero-value award—repeats with near-clockwork precision, indicating a pre-arranged or systematic disposition plan rather than opportunistic timing.
Notably, Rosty has not filed a single open-market purchase (coded “P”) in the dataset, and the total buy value is zero. The absence of any buy-side activity, combined with the consistent monthly sales, points to a clear net-selling bias. While the option exercises and awards replenish share counts, they do not represent new capital outlay, and the cash proceeds from sales have flowed out steadily. For investors tracking insider behavior, the message is unambiguous: Rosty is monetizing equity in FENC on a regular schedule, with no recent indication of a shift toward accumulation.
AI-assisted summary